The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure

Experimental and Clinical Cardiology

Volumn 14, Issue 3, 2009, Pages

  Walker, Jonathan R ^a   Singal, Pawan K ^a   Jassal, Davinder S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiac MRI; Cardiomyopathy; Echocardiography; Renin angiotensin system; Trastuzumab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRCA2 PROTEIN; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEMCITABINE; LISINOPRIL; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN P53; RAZOXANE; TRASTUZUMAB; ZOFENOPRIL;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG HALF LIFE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; MASTECTOMY; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 74549224505     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2002;2:93-5.
3. Marrett LD, De P, Airia P, Dryer D; Steering Committee of Canadian Cancer Statistics 2008. Cancer in Canada in 2008. CMAJ 2008;179:1163-70.
4. Pasche B. Recent advances in breast cancer genetics. In: Gradishar WJ, Wood WC, eds. Advances in Breast Cancer Management, Second Edition. New York: Springer, 2008:1-10.
5. Lalloo F, Varley J, Ellis D, et al; Early Onset Breast Cancer Study Group. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101-2.
6. Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA. Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008;113:2011-9.
7. Hazard HW, Hansen NM. Sentinel lymphadenectomy in breast cancer. Cancer Treat Res 2008;141:11-36.
8. Taghian AG, Powell SN. The role of radiation therapy for primary breast cancer. Surg Clin North Am 1999;79:1091-115.
9. Olver IN. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: Choosing which patient and when. Future Oncol 2008;4:125-31.
10. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000;27:13-9.
11. Plosker GL, Keam SJ. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 2006;66:449-75.
12. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 2000;60:3384-8.
13. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009;27:2638-44.
14. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21.
15. Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-12.
16. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
17. Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail 2008;14:437-44.
18. Harris LA, Yu Y, Donato B. Prescription patterns for metastatic breast cancer patients previously treated with anthracycline and taxane: An assessment in a United States managed care database. Am J Clin Oncol (Meeting Abstracts) 2007;25:17056.
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001;344:783-92.
20. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005;353:1673-84.
21. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. New Engl J Med 2007;357:39-51.
22. McKeage K, Perry CM. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209-43.
23. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumabrelated cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33.
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005;353:1659-72.
25. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008;8:324-33.
26. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: Current experience and future strategies. Ann Oncol 2008;19:1530-9.
27. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Williston Park) 2000;14:629-41.
28. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
29. Stickeler E, Klar M, Watermann D, et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: A multicenter phase II trial. Breast Cancer Res Treat 2009.
30. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
31. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: Course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58.
32. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med 1998;339:900-5.
33. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008;31:459-67.
34. Guarneri V, Frassoldati A, Bruzzi P, et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008;8:453-6.
35. Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 2008.
36. Smith I, Procter M, Gelber RD, et al; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
37. Yaal-Hahoshen N, Safra T. Herceptin (trastuzumab): Adjuvant and neoadjuvant trials. Isr Med Assoc J 2006;8:416-21.
38. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
39. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65.
40. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173-83.
41. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-15.
42. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-9.
43. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl 12):60-70.
44. Chien KR. Myocyte survival pathways and cardiomyopathy: Implications for trastuzumab cardiotoxicity. Semin Oncol 2000;27:9-14
45. Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail 2008;14:437-44.
46. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
47. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004;59:1-12.
48. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
49. Qiu Y, Ravi L, Kung HJ. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998;393:83-5.
50. Worthylake R, Wiley HS. Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu. J Biol Chem 1997;272:8594-601.
51. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 1990;248:79-83.
52. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.
53. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002;99:8880-5.
54. Gordon LI, Burke MA, Singh ATK, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009;284:2080-7.
55. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004;44:2231-8.
56. Jones AL, Barlow M, Barrett-Lee PJ, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92.
57. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 2005;23:2900-2.
58. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.
59. de Azambuja E, Bedard P, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: What have we learned so far? Targeted Oncol 2009;4:77-88.
60. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008;10:5.
61. Jassal DS, Han S-Y, Hans C, et al. Utility of tissue doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009;22:418-24.
62. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:1333-40.
63. Cvetković RS, Scott LJ. Dexrazoxane : A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005;65:1005-24.
64. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. New Engl J Med 1992;327:685-91.
65. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-90.
66. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Engl J Med 1991;325:293-302.
67. Jensen BV, Nielsen SL, Jensen TS. Angiotensin-converting enzyme inhibitor in the treatment of epirubicin-induced dilated cardiomyopathy. Ugeskr Laeger 1997;159:1945-9.
68. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin- converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996;347:297-9.
69. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-81.
70. Machado V, Cabral A, Monteiro P, Goncalves L, Providencia LA. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol 2008;27:1277-96.
71. Armstrong SC. Anti-oxidants and apoptosis: Attenuation of doxorubicin induced cardiomyopathy by carvedilol. J Mol Cell Cardiol 2004;37:817-21.